Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

Rhea-AI Summary

Sangamo Therapeutics (Nasdaq: SGMO) said it will release its fourth quarter and full year 2025 financial results after market close on Monday, March 30, 2026. A public conference call and webcast is set for 4:30 p.m. Eastern on March 30, 2026, followed by a replay available under Events.

Participants must register to receive dial‑in numbers and a unique passcode or use a dial‑out option; the live webcast link is on the company website in Investors and Media.

News Market Reaction – SGMO

-2.73%

1 alert

-2.73% Session close to close

-3.7% Trough Tracked

$133.81M Market Cap

4.65K Volume

In the Mar 20 session, SGMO declined 2.73%, reflecting a moderate negative market reaction. Argus tracked a trough of -3.7% from its starting point during tracking.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Sangamo’s Q4 and full-year 2025 results, with a public call...

Analysis

This announcement sets the timetable for Sangamo’s Q4 and full-year 2025 results, with a public call on March 30, 2026 at 4:30 p.m. Eastern. Context from recent filings shows a company balancing regulatory progress in Fabry disease with tight liquidity, including a roughly $25.0 million offering and disclosed going‑concern risks. Investors may focus on updated cash figures, runway, and any changes to clinical or financing plans during the upcoming call.

Key Figures

Results period: Q4 and full year 2025 Earnings release date: March 30, 2026 Earnings call time: 4:30 p.m. Eastern

3 metrics

Results period Q4 and full year 2025 Upcoming earnings release coverage

Earnings release date March 30, 2026 Scheduled after market close

Earnings call time 4:30 p.m. Eastern Start time for public conference call

Previous Earnings Reports

5 past events · Latest: Nov 06 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 06	Q3 2025 results	Positive	-16.3%	Reported Q3 2025 results and Fabry/neurology updates with detailed STAAR data.
Oct 30	Q3 call scheduled	Neutral	+4.5%	Announced timing of Q3 2025 financial results release and conference call.
Aug 07	Q2 2025 results	Positive	-5.3%	Reported Q2 2025 results with positive STAAR data and reduced net loss.
Jul 31	Q2 call scheduled	Neutral	+4.6%	Scheduled Q2 2025 financial results release and earnings call details.
May 12	Q1 2025 results	Positive	-38.4%	Reported Q1 2025 results with Lilly license, milestones, and equity offering.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Earnings reports with business updates have often been followed by double-digit declines, while simple earnings call announcements have seen modest gains.

Recent Company History

Recent history shows a mix of financing stress and regulatory progress. Earnings updates in Q1–Q3 2025 paired Fabry and neurology milestones with net losses and equity raises, and shares fell sharply after several of these releases. By contrast, prior earnings call scheduling notices on May 12 and July 31, 2025 coincided with small gains. Today’s Q4 and full-year 2025 call announcement fits this pattern of regular quarterly communication amid ongoing clinical and financial restructuring.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2025 financial results after the market closes on Monday, March 30, 2026.

The company will hold a conference call at 4:30 p.m. Eastern on Monday, March 30, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.

Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.

A replay will be available following the conference call, accessible under Events.

About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn.

Investor Relations and Media Inquiries
Louise Wilkie
ir@sangamo.com
media@sangamo.com

FAQ

When will Sangamo Therapeutics (SGMO) release its Q4 and full year 2025 results?

The company will release fourth quarter and full year 2025 results after market close on March 30, 2026. According to the company, the release timing is followed by a public conference call and live webcast at 4:30 p.m. Eastern that same day.

What time is the Sangamo Therapeutics (SGMO) earnings call on March 30, 2026?

The earnings call is scheduled for 4:30 p.m. Eastern on March 30, 2026. According to the company, the call will review financial results and provide business updates and will be open to the public via webcast and dial‑in.

How can investors access the Sangamo (SGMO) March 30, 2026 conference call and webcast?

Investors should register via the company link to receive dial‑in numbers, a unique passcode, or use the dial‑out option for instant phone connection. According to the company, the live webcast link is also on the Investors and Media Events page.

Will Sangamo (SGMO) provide a replay of the March 30, 2026 earnings call?

Yes. A replay will be available after the conference call under Events on the company website. According to the company, the replay can be accessed in the Investors and Media section after the live webcast concludes.

Is registration required to join the Sangamo Therapeutics (SGMO) Q4 2025 earnings call?

Registration is not strictly required but is recommended to receive dial‑in details and passcode or to enable dial‑out. According to the company, registrants will be given connection options and are advised to join about 10 minutes early.

What will Sangamo (SGMO) cover during the March 30, 2026 conference call?

The company will review its fourth quarter and full year 2025 financial results and provide business updates during the call. According to the company, management will discuss results and answer questions via the public webcast and dial‑in connection.